Rapid antigen test

LivePerson And Innova Medical Group Announce Partnership For AI-powered, At-home COVID-19 Rapid Testing

Retrieved on: 
Wednesday, March 10, 2021

NEW YORK, March 10, 2021 /PRNewswire/ -- LivePerson , a global leader in conversational AI, in partnership with Innova Medical Group , the world's largest manufacturer of rapid antigen test kits and leader in COVID-19 testing solutions globally, today announced the launch of BELLA Health with Innova , a first-of-its-kind COVID-19 rapid testing experience with AI-guided instructions to ensure accuracy.

Key Points: 
  • NEW YORK, March 10, 2021 /PRNewswire/ -- LivePerson , a global leader in conversational AI, in partnership with Innova Medical Group , the world's largest manufacturer of rapid antigen test kits and leader in COVID-19 testing solutions globally, today announced the launch of BELLA Health with Innova , a first-of-its-kind COVID-19 rapid testing experience with AI-guided instructions to ensure accuracy.
  • LivePerson and Innova have launched BELLA Health with Innova, a first-of-its-kind COVID-19 rapid testing experience.
  • Innova Medical Group currently produces 15 million highly accurate and cost-effective rapid antigen tests per day for global use.
  • Innova Medical Group, Inc. delivers better global health outcomes with its deep expertise in testing and unique offerings in diagnostic medical devices and services that help tackle some of the world's most challenging healthcare problems.

Abingdon Health Plc signs distribution agreement with BioSure UK

Retrieved on: 
Wednesday, March 10, 2021

Abingdon Health is a world leading developer and manufacturer of high-quality rapid tests across all industry sectors, including healthcare and COVID-19.

Key Points: 
  • Abingdon Health is a world leading developer and manufacturer of high-quality rapid tests across all industry sectors, including healthcare and COVID-19.
  • Abingdon Health aims to support the increase in need for rapid results across many industries and locations and produces lateral flow tests in areas such as infectious disease, clinical testing including companion diagnostics, animal health and environmental testing.
  • Founded in 2008, Abingdon Health is headquartered in York, England.
  • Since launching in 2015, theBioSUREHIVSelf Testhas helped people throughout the UK and the world, to #knowyourstatus.

Avacta Signs Diagnostic Licensing Deal with Biokit

Retrieved on: 
Tuesday, March 9, 2021

The license agreement follows an extensive evaluation by Biokit of certain Affimer reagents to detect a key analyte.

Key Points: 
  • The license agreement follows an extensive evaluation by Biokit of certain Affimer reagents to detect a key analyte.
  • Under the terms of the agreement Biokit has the right to develop, manufacture and commercialise through original equipment manufacturer (OEM) partners a diagnostic immunoassay for this analyte.
  • Avactas diagnostics business model combines development of a wholly owned pipeline of products, including the SARS-CoV-2 rapid antigen test, with licensing of Affimer reagents to diagnostic development partners such as Biokit.
  • Dr Marta Palicio, Innovation Director of Biokit commented:
    "Biokit is very pleased to have reached this agreement with Avacta.

Ortho's New COVID-19 Total and IgG Antibody Tests Receive CE Mark for Semi-Quantitative Results

Retrieved on: 
Monday, March 8, 2021

With both assays showing 100% specificityiand excellent sensitivity,iiOrtho's new COVID-19 Total 2 and IgG 2 antibody assays help clinicians understand each patient's adaptive immune response (acquired naturally post-infection or through vaccination) to SARS-CoV-2.

Key Points: 
  • With both assays showing 100% specificityiand excellent sensitivity,iiOrtho's new COVID-19 Total 2 and IgG 2 antibody assays help clinicians understand each patient's adaptive immune response (acquired naturally post-infection or through vaccination) to SARS-CoV-2.
  • These analyzers normally run a broad menu of over 150 different tests from blood and body fluid samples.
  • These new anti-SARS-CoV-2 antibody assays are the latest addition to Ortho's COVID-19 solutions, which include COVID-19 antibody tests and an antigen test .
  • Ortho plans to manufacture several million COVID-19 antibody tests each month in Pencoed, Wales.

Ortho's New COVID-19 Total and IgG Antibody Tests Receive CE Mark for Semi-Quantitative Results

Retrieved on: 
Monday, March 8, 2021

- These new anti-SARS-CoV-2 antibody assays are the latest addition to Ortho's COVID-19 solutions, which include COVID-19 antibody tests and an antigen test .

Key Points: 
  • - These new anti-SARS-CoV-2 antibody assays are the latest addition to Ortho's COVID-19 solutions, which include COVID-19 antibody tests and an antigen test .
  • With both assays showing 100% specificityiand excellent sensitivity,iiOrtho's new COVID-19 Total 2 and IgG 2 antibody assays help clinicians understand each patient's adaptive immune response (acquired naturally post-infection or through vaccination) to SARS-CoV-2.
  • These new anti-SARS-CoV-2 antibody assays are the latest addition to Ortho's COVID-19 solutions, which include COVID-19 antibody tests and an antigen test .
  • Ortho plans to manufacture several million COVID-19 antibody tests each month in Pencoed, Wales.

Avacta’s Rapid Antigen Test Is Confirmed to Detect SARS-CoV-2 New Variants

Retrieved on: 
Monday, March 8, 2021

Some of these variants are more infectious, and therefore more rapidly transmissible, and have the potential to become dominant strains.

Key Points: 
  • Some of these variants are more infectious, and therefore more rapidly transmissible, and have the potential to become dominant strains.
  • Avacta has carried out analytical tests with the spike proteins isolated from both the B117 and D614G variants, and has confirmed that its AffiDX SARS-CoV-2 rapid antigen lateral flow test detects both of these variants as well as the original strain.
  • We will continue to monitor the performance of the Affimer reagents with future dominant variants as they become available to us.
  • Disclaimer: AffiDX SARS-CoV-2 Lateral Flow Rapid Antigen Test not currently for sale in the United States.

Intrivo Teams with Amazon Business to Offer COVID-19 Rapid Tests

Retrieved on: 
Thursday, March 4, 2021

Intrivo gives faster, easier access to accurate, point-of-care COVID-19 antigen tests, now available on Amazon Business.

Key Points: 
  • Intrivo gives faster, easier access to accurate, point-of-care COVID-19 antigen tests, now available on Amazon Business.
  • As the exclusive commercialization partner for CareStartTM COVID-19 tests in the U.S., Intrivo will handle all orders and fulfillment of its CareStartTM Antigen kit for approved buyers.
  • Intrivo will be better able to provide healthcare practitioners with faster, streamlined access to accurate, quality COVID-19 rapid antigen tests at higher volumes by utilizing Amazon Business, which serves millions of customers worldwide and 84 of the top 100 health systems in the U.S.
    "Working with Amazon Business to distribute our antigen tests in their online store is a major milestone for our company," said Reeve Benaron, Founder, Chairman and CEO of Intrivo.
  • Intrivo's work with Amazon Business is the latest in the testing provider's efforts to expand distribution to more customers in need.

Co-Diagnostics New Rapid PCR Point-of-Care and at Home Testing Platform to Detect Covid-19 and Other Diseases Using CoPrimer™ Technology

Retrieved on: 
Tuesday, March 2, 2021

The platform chemistry was created by Co-Diagnostics utilizing proprietary CoPrimer technology, Direct Saliva extraction-free protocols, and freeze-dried reagents.

Key Points: 
  • The platform chemistry was created by Co-Diagnostics utilizing proprietary CoPrimer technology, Direct Saliva extraction-free protocols, and freeze-dried reagents.
  • With this platform, Co-Diagnostics plans to revolutionize the availability of accurate, fast and economical PCR tests as regular Covid-19 testing becomes part of the long-term protocol for many organizations.
  • The rapid gold-standard PCR results from this testing platform would be differentiated from less accurate antigen tests.
  • In addition, PCR may even detect the presence of genetic material of the SARS-CoV-2 virus being carried by vaccinated patients.

Innova Medical Group Announces New Chairman and Chief Medical Officer

Retrieved on: 
Monday, March 1, 2021

1, 2021 /PRNewswire/ --Innova Medical Group, Inc., the world's largest manufacturer of rapid antigen test kits and leader in COVID-19 testing solutions globally, announced today the appointment of Sean Rogers as Chairman of Innova Medical Group, and Todd Malan, M.D., as Innova's Chief Medical Officer.

Key Points: 
  • 1, 2021 /PRNewswire/ --Innova Medical Group, Inc., the world's largest manufacturer of rapid antigen test kits and leader in COVID-19 testing solutions globally, announced today the appointment of Sean Rogers as Chairman of Innova Medical Group, and Todd Malan, M.D., as Innova's Chief Medical Officer.
  • "Since the beginning of the pandemic, Innova's rapid and accessible antigen tests have proven to be a critical tool in comprehensive testing regimes to contain COVID-19 and save lives," said Sean Rogers, newly appointed Chairman of Innova Medical Group.
  • Rogers has also been named Chief Executive Officer of Pasaca Capital, the parent company of Innova Medical Group.
  • Innova Medical Group, Inc. delivers better global health outcomes with its deep expertise in testing and unique offerings in diagnostic medical devices and services that help tackle some of the world's most challenging healthcare problems.

Therma Bright Enters into Clinical Trial Agreement for its AcuVid(TM) COVID-19 Rapid Saliva-Based Antigen Test

Retrieved on: 
Friday, February 26, 2021

The testing site will allow the Company to complete the clinical trial quickly followed by submission of the data to both the FDA and Health Canada.

Key Points: 
  • The testing site will allow the Company to complete the clinical trial quickly followed by submission of the data to both the FDA and Health Canada.
  • With a clinical trial agreement signed, Therma Bright can seek Research Ethics Board (REB) approval and Health Canada approval for the proposed trial.
  • Therma Bright is in discussions to complete additional clinical trials with the AcuVidTM rapid saliva-based antigen test in the US and other international locations.
  • As the regulations regarding home use become clearer and standardised, the test will be introduced as a home-use test.